arrow
M

Miguel Paja

Biobizkaia Health Research Institute
H指数:10
被引数:346

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

OC10.3 - ECE_2879 - Dynamic postoperative PTH as a strong predictor of hypoparathyroidism after total thyroidectomy: a large cohort analysis

OC10.3 - ECE_2879 - 动态术后甲状旁腺素作为全甲状腺切除术后甲状旁腺功能减退的强预测因子:一项大型队列分析

2026-08-100
OAAI
P79 - ECE_2596 - Predicting permanent postoperative hypoparathyroidism using preoperative and intraoperative PTH dynamics

P79 - ECE_2596 - 预测永久性术后甲状旁腺功能减退症,使用术前和术中PTH动力学

2026-08-100
OAAI
P267 - ECE_1010 - Glucocorticoid-induced positive feedback in Cushing disease: insights from a multicenter cohort

P267 - ECE_1010 - 库欣综合征中糖皮质激素诱导的正反馈:来自多中心队列的见解

2026-08-100
OAAI
Glucocorticoid-Induced Positive Feedback in Cushing Disease: Insights From a Spanish Multicenter Cohort

库欣病中糖皮质激素诱导的正反馈:来自西班牙多中心队列的见解

2026-06-010
OAAI
Mineralocorticoid Receptor Antagonist Pre-Adrenalectomy in Primary Aldosteronism

醛固酮受体拮抗剂术前肾上腺切除术在原发性醛固酮增多症中的应用

2025-11-010
OAAI
Real-World Data on the Efficacy and Safety of Osilodrostat in Patients with Cushing’s Disease in Spain

西班牙人群中库欣病患者使用奥西洛多罗司治疗的有效性与安全性真实世界数据

2025-10-250
OAAI
External validation of the S-GRAS score for predicting recurrence in patients with adrenocortical carcinoma: implications for adjuvant mitotane therapy

S-GRAS评分在预测肾上腺皮质癌患者复发中的外部验证:对辅助米托坦治疗的启示

2025-08-140
PRE
Efficacy and safety of medical treatment of primary aldosteronism: a real-world data study in Spain

原发性醛固酮增多症药物治疗的有效性与安全性:一项西班牙真实世界数据研究

2025-07-310
OAAI
Impaired renal function in patients with permanent hypoparathyroidism after thyroidectomy: analysis of a nationwide cohort in Spain
2025-03-010
PRE
Outcomes of transsphenoidal surgery for pituitary adenomas in Spain: a retrospective multicenter study
2025-02-210
OAAI
Does Adjuvant Mitotane Impact Cure Rates in Adrenocortical Carcinoma? Insights From the ICARO-GETTHI/SEEN Registry
2025-02-140
OA
Sellar and perisellar meningiomas: effects on pituitary function in a Spanish cohort observational study
2024-12-280
PRE
Prevalence of chronic postsurgical hypoparathyroidism not adequately controlled: an analysis of a nationwide cohort of 337 patients
2024-09-250
OAAI
Pegvisomant and pasireotide in PRL and GH co-secreting vs GH-secreting Pit-NETs (vol 31, e240043, 2024)
2024-09-010
PRE
Impact of primary aldosteronism on kidney function: results from the SPAIN-ALDO registry
2024-07-051
PRE
Pegvisomant and pasireotide in PRL and GH co-secreting vs GH-secreting Pit-NETs
2024-05-074
PRE
Differences Between GH- and PRL-Cosecreting and GH-Secreting Pituitary Adenomas: a Series of 604 Cases

GH和PRL共分泌与分泌GH的垂体腺瘤之间的差异: 一系列604例

2024-03-045
OA
Differences in the clinical and hormonal presentation of patients with familial and sporadic primary aldosteronism
2024-03-012
OAAI
Incident comorbidities in patients with chronic hypoparathyroidism after thyroidectomy: a multicenter nationwide study
2024-02-283
OAAI